Literature DB >> 26510622

Pharmacological Targeting of AMP-Activated Protein Kinase and Opportunities for Computer-Aided Drug Design.

Marie Miglianico1, Gerry A F Nicolaes1, Dietbert Neumann1.   

Abstract

As a central regulator of metabolism, the AMP-activated protein kinase (AMPK) is an established therapeutic target for metabolic diseases. Beyond the metabolic area, the number of medical fields that involve AMPK grows continuously, expanding the potential applications for AMPK modulators. Even though indirect AMPK activators are used in the clinics for their beneficial metabolic outcome, the few described direct agonists all failed to reach the market to date, which leaves options open for novel targeting methods. As AMPK is not actually a single molecule and has different roles depending on its isoform composition, the opportunity for isoform-specific targeting has notably come forward, but the currently available modulators fall short of expectations. In this review, we argue that with the amount of available structural and ligand data, computer-based drug design offers a number of opportunities to undertake novel and isoform-specific targeting of AMPK.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26510622     DOI: 10.1021/acs.jmedchem.5b01201

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Acute activation of endothelial AMPK surprisingly inhibits endothelium-dependent hyperpolarization-like relaxations in rat mesenteric arteries.

Authors:  Hui Chen; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2019-07-04       Impact factor: 8.739

2.  A Novel Phenylchromane Derivative Increases the Rate of Glucose Uptake in L6 Myotubes and Augments Insulin Secretion from Pancreatic Beta-Cells by Activating AMPK.

Authors:  Naomi Rozentul; Yosef Avrahami; Moran Shubely; Laura Levy; Anna Munder; Guy Cohen; Erol Cerasi; Shlomo Sasson; Arie Gruzman
Journal:  Pharm Res       Date:  2017-10-05       Impact factor: 4.200

3.  Identification of Direct Activator of Adenosine Monophosphate-Activated Protein Kinase (AMPK) by Structure-Based Virtual Screening and Molecular Docking Approach.

Authors:  Tonghui Huang; Jie Sun; Shanshan Zhou; Jian Gao; Yi Liu
Journal:  Int J Mol Sci       Date:  2017-06-30       Impact factor: 5.923

Review 4.  Adenosine Monophosphate (AMP)-Activated Protein Kinase: A New Target for Nutraceutical Compounds.

Authors:  Fabiola Marín-Aguilar; Luis E Pavillard; Francesca Giampieri; Pedro Bullón; Mario D Cordero
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

5.  Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation.

Authors:  Alicia Bort; Sergio Quesada; Ágata Ramos-Torres; Marta Gargantilla; Eva María Priego; Sophie Raynal; Franck Lepifre; Jose M Gasalla; Nieves Rodriguez-Henche; Ana Castro; Inés Díaz-Laviada
Journal:  Sci Rep       Date:  2018-03-12       Impact factor: 4.379

6.  Target-based drug discovery through inversion of quantitative structure-drug-property relationships and molecular simulation: CA IX-sulphonamide complexes.

Authors:  Petar Žuvela; J Jay Liu; Myunggi Yi; Paweł P Pomastowski; Gulyaim Sagandykova; Mariusz Belka; Jonathan David; Tomasz Bączek; Krzysztof Szafrański; Beata Żołnowska; Jarosław Sławiński; Claudiu T Supuran; Ming Wah Wong; Bogusław Buszewski
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

7.  ADP is the dominant controller of AMP-activated protein kinase activity dynamics in skeletal muscle during exercise.

Authors:  Ian F Coccimiglio; David C Clarke
Journal:  PLoS Comput Biol       Date:  2020-07-30       Impact factor: 4.475

8.  AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma.

Authors:  Nicolas Belforte; Jessica Agostinone; Luis Alarcon-Martinez; Deborah Villafranca-Baughman; Florence Dotigny; Jorge L Cueva Vargas; Adriana Di Polo
Journal:  Mol Neurodegener       Date:  2021-06-29       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.